Catriona Yale, Chief Development Officer at Akero Therapeutics, Inc. (AKRO), sold 89,448 shares at $57.01 ($5.0M) on 2025-01-27, disclosed to the SEC on 2025-01-31.
Scheduled sale ($5.0M) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $55.15 | 25,907 | $1.4M | 28.7% |
| 2 | $55.15 | 25,907 | $1.4M | 28.7% |
| 3 | $55.95 | 14,467 | $809K | 16.3% |
| 4 | $55.95 | 14,467 | $809K | 16.3% |
| 5 | $57.01 | 8,700 | $496K | 10.0% |
| Total | $55.59 avg | 89,448 |
| $5.0M |
| 100% |
| Filing → |
| AKRO | SELL | 2025-06-20 | $179K | — | Filing → |
| AKRO | SELL | 2025-06-20 | $876K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $151K | — | Filing → |